BRVT121

Hepatocellular carcinoma

Phase IActive

Key Facts

Indication

Hepatocellular carcinoma

Phase

Phase I

Status

Active

Company

Biorevert uses network‑control systems biology to develop non‑lethal therapies that revert cancer and aging cells to healthy states.

Drug	Company	Phase	Status
Namodenoson (CF102)	Can Fite Biopharma	Phase IIb/III	Active
GC-101	Genocury Biotech	Preclinical	Active
DCR-MYC	Dicerna Pharmaceuticals	Preclinical	Discontinued
RYZ801	RayzeBio	Preclinical	Active
CT011	CARsgen Therapeutics	Phase II	Active
BRVT101	Biorevert	Preclinical	Active
BRVT151	Biorevert	Phase I	Active
HCC Diagnostic Test	Senseera	Clinical POC	Active
RG6139 (RO7247669)	Chugai Pharmaceutical	Phase III	Active
ALN-BCAT	Alnylam Pharmaceuticals	Phase 1	Active
HCC Program	Arcellx	Discovery	Active
TTFields	Novocure	Pilot	Active